Sumitomo Pharma America Inc - Company Profile
Powered by 
All the data and insights you need on Sumitomo Pharma America Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Sumitomo Pharma America Inc Strategy Report
- Understand Sumitomo Pharma America Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sumitomo Pharma America Inc (Sumitomo Pharma), formerly Sunovion Pharmaceuticals Inc, is a research-based pharmaceutical company. It discovers, develops, and marketize therapeutic products that focus on the treatment of the central nervous system and respiratory disorders. Its major products include eslicarbazepine acetate tablets, lurasidone HCl tablets, relugolix, estradiol, and norethindrone acetate tablets, vibegron tablets, relugolix tablets, and allogeneic processed thymus tissue–agdc. The company’s product candidates are intended for the treatment of schizophrenia, neuropathic pain, bipolar depression, treatment-resistant depression, agitation in Alzheimer's disease, and women’s healthcare products among others. It has partnerships with various pharmaceutical companies such as Psychogenics and others. Sumitomo Pharma is headquartered in Marlborough, Massachusetts, the US.
Headquarters
United States of America
Address
84 Waterford Drive, Marlborough, Massachusetts, 01752
Website
www.sunovion.com
Telephone
1 508 4816700
No of Employees
1,200
Industry
Pharmaceuticals and Healthcare
Sumitomo Pharma America Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Latuda (lurasidone HCi) Tablets |
| Aptiom (eslicarbazepine acetate) Tablets |
| Myfembree |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Corporate Changes/Expansions | In July, the company changed its name from Sunovion Pharmaceuticals Inc to Sumitomo Pharma America, Inc. |
| 2021 | Contracts/Agreements | In September, the company entered into an agreement with BIAL, in which Sunovion granted commercial license rights for apomorphine sublingual film (APL-130277) in Europe. |
| 2020 | Contracts/Agreements | In October, the company entered into an promotion agreement with Urovant Sciences to promote vibegron in the primary care segment. |
Competitor Comparison
| Key Parameters | Sumitomo Pharma America Inc | Alexion Pharmaceuticals Inc | Acadia Pharmaceuticals Inc | OptiNose Inc | Curemark LLC |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Marlborough | Boston | San Diego | Yardley | Rye BrooK |
| State/Province | Massachusetts | Massachusetts | California | Pennsylvania | New York |
| No. of Employees | 1,200 | 3,000 | 597 | 132 | - |
| Entity Type | Private | Private | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Myrtle Potter | President; Director; Chief Executive Officer | Executive Board | 2023 | - |
| Armin Szegedi | Director; Chief Medical Officer | Executive Board | 2023 | - |
| Tsutomu Nakagawa, Ph.D. | Chief Strategy Officer | Senior Management | 2023 | - |
| Tara Soni | Chief Legal Officer | Senior Management | 2023 | - |
| Betzy Estrada | Chief Human Resources Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer